IGF1R and cancer: Thus, despite a plethora of strong preclinical data supporting the rationale for IGF-1R-targeted cancer therapy, the generally disappointing clinical results, as revealed by figitumumab, R1507 (clinical development suspended in December 2009), and others [43], have pointed to a future direction that will focus on identification and validation of predictive biomarkers, as well as the investigation of more rational combinations with other anticancer agents to combat common resistance mechanisms developed from blockade of IGF-1R alone.